Hub : Traits

Reaction time premature initiation rate

Premature initiations per opportunity computed by dividing the number of premature initiations by the number of completed trials in the last three 18-minute sessions for males and females [ratio]

Tags: Behavior · Reaction time

Project: p50_david_dietz

1 locus · 1 gene with independent associations · 1 total associated gene

Significant Loci

#	Chr	Start pos	End pos	# assoc genes	# joint models	Best TWAS P	Best GWAS P	Cond GWAS P	Joint genes
1	chr2	175255218	176649376	1	1	1.63e-07	2.49e-01	9.31e-41	Ilf2

Pleiotropic Associations

Trait	Chi2 ratio	# genes+	# genes++	% genes++	Corr	Corr P	Genes
Left kidney weight	2.28	1	0	0	0	1e+00	Ilf2
Right kidney weight	2.38	1	0	0	0	1e+00	Ilf2
Liver weight, left	2.88	1	0	0	0	1e+00	Ilf2
Intraocular pressure	5.72	1	0	0	0	1e+00	Ilf2
Extensor digitorum longus weight	1.85	1	0	0	0	1e+00	Ilf2
Patch foraging total patch changes 12 sec	5.98	1	0	0	0	1e+00	Ilf2
Patch foraging time to switch 0 sec	2.52	1	0	0	0	1e+00	Ilf2
Patch foraging water rate 18 sec	3.4	1	0	0	0	1e+00	Ilf2
Locomotor activity	3.02	1	0	0	0	1e+00	Ilf2
Locomotor testing distance	2.69	1	0	0	0	1e+00	Ilf2
Light reinforcement 2	4.21	1	0	0	0	1e+00	Ilf2
Reaction time mean	2.9	1	0	0	0	1e+00	Ilf2
Reaction time mean AUC	3.59	1	0	0	0	1e+00	Ilf2
Reaction time premature initiations	12.93	1	0	0	0	1e+00	Ilf2
Std. dev. reaction times	3.86	1	0	0	0	1e+00	Ilf2
Social response proportion	11.26	1	0	0	0	1e+00	Ilf2
Social time	4.65	1	0	0	0	1e+00	Ilf2
Conditioned reinforcement - inactives	4.5	1	0	0	0	1e+00	Ilf2
Conditioned locomotion	6.8	1	0	0	0	1e+00	Ilf2
Intermittent access intake day 1-15 change	5.14	1	0	0	0	1e+00	Ilf2
Intermittent access intake escalation 2	6.44	1	0	0	0	1e+00	Ilf2
Intermitt. access escalation Index	4.8	1	0	0	0	1e+00	Ilf2
Intermittent access day 1 locomotion	5.42	1	0	0	0	1e+00	Ilf2
Intermittent access day 15 total locomotion	5.95	1	0	0	0	1e+00	Ilf2
Intermittent access total locomotion	6.46	1	0	0	0	1e+00	Ilf2
Intermittent access standard deviation	3.81	1	0	0	0	1e+00	Ilf2
Progressive ratio test 2 inactive lever presses	3.96	1	0	0	0	1e+00	Ilf2
Short access day 10 total infusions	3.77	1	0	0	0	1e+00	Ilf2
Short access day 10 total locomotion	3.47	1	0	0	0	1e+00	Ilf2
Locomotion velocity, session 2	6.62	1	0	0	0	1e+00	Ilf2
Stereotopy head waving bouts, day 3	7.08	1	0	0	0	1e+00	Ilf2
Stereotopy head waving duration, day 3	5.56	1	0	0	0	1e+00	Ilf2
Locomotion velocity, session 8	12.45	1	0	0	0	1e+00	Ilf2
Condit. Reinf. inactive responses	3.83	1	0	0	0	1e+00	Ilf2
Condit. Reinf. lever presses	10.84	1	0	0	0	1e+00	Ilf2
Novel to familiar place preference ratio	7.16	1	0	0	0	1e+00	Ilf2
Novelty place preference	6.43	1	0	0	0	1e+00	Ilf2
Time in novel zone, NPP test	4.7	1	0	0	0	1e+00	Ilf2
Pavlov. Cond. lever latency	21.9	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. magazine entry latency	28.91	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. change in total contacts	18.74	1	0	0	0	1e+00	Ilf2
Pavlov. Cond. index score	34.08	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. latency score	30.82	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. lever contacts	37.24	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. magazine entry number	42.75	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. intertrial magazine entries	13.5	1	0	0	0	1e+00	Ilf2
Pavlov. Cond. lever-magazine prob. diff.	35.53	1	1	100	0	1e+00	Ilf2
Pavlov. Cond. response bias	41.38	1	1	100	0	1e+00	Ilf2
Bone volume	3.15	1	0	0	0	1e+00	Ilf2
Bone: cortical area	8.85	1	0	0	0	1e+00	Ilf2
Bone: elastic work	4.68	1	0	0	0	1e+00	Ilf2
Bone: endosteal estimation	5.57	1	0	0	0	1e+00	Ilf2
Bone: endosteal perimeter	2.98	1	0	0	0	1e+00	Ilf2
Bone: final force	22.01	1	1	100	0	1e+00	Ilf2
Bone: final moment	20.22	1	1	100	0	1e+00	Ilf2
Bone: marrow area	5.59	1	0	0	0	1e+00	Ilf2
Bone: maximum force	24.61	1	1	100	0	1e+00	Ilf2
Bone: maximum moment	21.5	1	1	100	0	1e+00	Ilf2
Bone: minimum diameter	7.24	1	0	0	0	1e+00	Ilf2
Bone: periosteal estimation	7.49	1	0	0	0	1e+00	Ilf2
Bone: periosteal perimeter	4.34	1	0	0	0	1e+00	Ilf2
Bone: post-yield work	5.96	1	0	0	0	1e+00	Ilf2
Bone: stiffness	12.05	1	0	0	0	1e+00	Ilf2
Distance traveled before self-admin	4.78	1	0	0	0	1e+00	Ilf2
Distance traveled after self-admin	5.06	1	0	0	0	1e+00	Ilf2
Delta time in open arm before/after self-admin	7.55	1	0	0	0	1e+00	Ilf2
Time in open arm before self-admin	9.47	1	0	0	0	1e+00	Ilf2
Time to tail flick, test, before self-admin	5.28	1	0	0	0	1e+00	Ilf2
Delta time to tail flick, test, before/after SA	4.98	1	0	0	0	1e+00	Ilf2
Ambulatory time after self-admin	5.09	1	0	0	0	1e+00	Ilf2
Bouts of movement, locomotor time 2	4.23	1	0	0	0	1e+00	Ilf2
Total resting periods, locomotor time 2	3.88	1	0	0	0	1e+00	Ilf2
Rest time, locomotor task time 2	4.3	1	0	0	0	1e+00	Ilf2
Distance moved, locomotor task time 2	9.43	1	0	0	0	1e+00	Ilf2
Seeking ratio, delayed vs. immediate footshock	3.47	1	0	0	0	1e+00	Ilf2
Locomotion in novel chamber	4.37	1	0	0	0	1e+00	Ilf2
Progressive ratio	12.89	1	0	0	0	1e+00	Ilf2
Seeking ratio, punishment vs. effort	3.9	1	0	0	0	1e+00	Ilf2
Run reversals in cocaine runway, males	6.86	1	0	0	0	1e+00	Ilf2
Latency to leave start box in cocaine runway	7.72	1	0	0	0	1e+00	Ilf2
Latency to leave start box in cocaine runway, M	14.76	1	0	0	0	1e+00	Ilf2
Cd content in liver	13.38	1	0	0	0	1e+00	Ilf2
Na content in liver	4.96	1	0	0	0	1e+00	Ilf2
Sr content in liver	7.23	1	0	0	0	1e+00	Ilf2
Zn content in liver	4.99	1	0	0	0	1e+00	Ilf2

Associations by panel

Tissue	RNA modality	# hits	% hits/tests	Avg chisq
Adipose	alternative polyA	0	0	1.31
Adipose	alternative TSS	0	0	1.27
Adipose	gene expression	0	0	1.35
Adipose	isoform ratio	0	0	1.25
Adipose	intron excision ratio	0	0	1.19
Adipose	mRNA stability	0	0	1.35
BLA	alternative polyA	0	0	1.3
BLA	alternative TSS	0	0	1.33
BLA	gene expression	0	0	1.37
BLA	isoform ratio	0	0	1.35
BLA	intron excision ratio	0	0	1.27
BLA	mRNA stability	0	0	1.45
Brain	alternative polyA	0	0	1.32
Brain	alternative TSS	0	0	1.35
Brain	gene expression	0	0	1.36
Brain	isoform ratio	0	0	1.32
Brain	intron excision ratio	0	0	1.34
Brain	mRNA stability	0	0	1.37
Eye	alternative polyA	0	0	1.2
Eye	alternative TSS	0	0	1.3
Eye	gene expression	0	0	1.34
Eye	isoform ratio	0	0	1.37
Eye	intron excision ratio	0	0	1.27
Eye	mRNA stability	0	0	1.43
IL	alternative polyA	0	0	1.29
IL	alternative TSS	0	0	1.4
IL	gene expression	0	0	1.43
IL	isoform ratio	0	0	1.35
IL	intron excision ratio	0	0	1.28
IL	mRNA stability	0	0	1.4
LHb	alternative polyA	0	0	1.3
LHb	alternative TSS	0	0	1.27
LHb	gene expression	0	0	1.43
LHb	isoform ratio	0	0	1.26
LHb	intron excision ratio	0	0	1.21
LHb	mRNA stability	0	0	1.35
Liver	alternative polyA	0	0	1.36
Liver	alternative TSS	0	0	1.3
Liver	gene expression	0	0	1.33
Liver	isoform ratio	0	0	1.32
Liver	intron excision ratio	0	0	1.37
Liver	mRNA stability	0	0	1.35
NAcc	alternative polyA	0	0	1.35
NAcc	alternative TSS	0	0	1.31
NAcc	gene expression	1	0	1.36
NAcc	isoform ratio	0	0	1.29
NAcc	intron excision ratio	0	0	1.35
NAcc	mRNA stability	0	0	1.4
OFC	alternative polyA	0	0	1.34
OFC	alternative TSS	0	0	1.36
OFC	gene expression	0	0	1.38
OFC	isoform ratio	0	0	1.38
OFC	intron excision ratio	0	0	1.28
OFC	mRNA stability	0	0	1.43
PL	alternative polyA	0	0	1.29
PL	alternative TSS	0	0	1.33
PL	gene expression	0	0	1.35
PL	isoform ratio	0	0	1.32
PL	intron excision ratio	0	0	1.34
PL	mRNA stability	0	0	1.39
pVTA	alternative polyA	0	0	1.33
pVTA	alternative TSS	0	0	1.28
pVTA	gene expression	0	0	1.38
pVTA	isoform ratio	0	0	1.36
pVTA	intron excision ratio	0	0	1.3
pVTA	mRNA stability	0	0	1.42
RMTg	alternative polyA	0	0	1.25
RMTg	alternative TSS	0	0	1.19
RMTg	gene expression	0	0	1.37
RMTg	isoform ratio	0	0	1.29
RMTg	intron excision ratio	0	0	1.32
RMTg	mRNA stability	0	0	1.39